Development of a personalized decision aid for breast cancer risk reduction and management

Por Ozanne, Elissa M, Howe, Rebecca, Omer, Zehra, Esserman, Laura J
Publicado em 2014

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

Por Esserman, Laura J, Ozanne, Elissa M, Dowsett, Mitch, Slingerland, Joyce M
Publicado em 2005

Aggregate Cost of Mammography Screening in the United States: Comparison of Current Practice and Advocated Guidelines

Por O’Donoghue, Cristina, Eklund, Martin, Ozanne, Elissa M., Esserman, Laura J.
Publicado em 2014

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer

Por Price, Elissa R, Wong, Jasmine, Mukhtar, Rita, Hylton, Nola, Esserman, Laura J
Publicado no World J Clin Cases (2015)

Major Histocompatibility Complex Class II Transcriptional Platform: Assembly of Nuclear Factor Y and Regulatory Factor X (RFX) on DNA Requires RFX5 Dimers

Por Jabrane-Ferrat, Nabila, Nekrep, Nada, Tosi, Giovanna, Esserman, Laura J., Peterlin, B. Matija
Publicado em 2002

Leukocyte composition of human breast cancer

Por Ruffell, Brian, Au, Alfred, Rugo, Hope S., Esserman, Laura J., Hwang, E. Shelley, Coussens, Lisa M.
Publicado em 2012

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Por Mukhtar, Rita A., Yau, Christina, Rosen, Mark, Tandon, Vickram J., Hylton, Nola, Esserman, Laura J.
Publicado em 2013

Monitoring the Implementation of Consultation Planning, Recording, and Summarizing in a Breast Care Center

Por Belkora, Jeffrey K., Loth, Meredith K., Chen, Daniel F., Chen, Jennifer Y., Volz, Shelley, Esserman, Laura J.
Publicado em 2008

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis

Por Belkora, Jeffrey K, Rugo, Hope S, Moore, Dan H, Hutton, David W, Chen, Daniel F, Esserman, Laura J
Publicado em 2009

Optimized Breast MRI Functional Tumor Volume as a Biomarker of Recurrence-Free Survival Following Neoadjuvant Chemotherapy

Por Jafri, Nazia F., Newitt, David C., Kornak, John, Esserman, Laura J., Joe, Bonnie N., Hylton, Nola M.
Publicado no J Magn Reson Imaging (2013)

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Por Cureton, Elizabeth L., Yau, Christina, Alvarado, Michael D., Krontiras, Helen, Ollila, David W., Ewing, Cheryl A., Monnier, Sindy, Esserman, Laura J.
Publicado no Ann Surg Oncol (2014)

Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ

Por Kumar, Anjali S., Chen, Daniel F., Au, Alfred, Chen, Yunn-Yi, Leung, Jessica, Garwood, Elisabeth R., Gibbs, Jessica, Hylton, Nola, Esserman, Laura J.
Publicado em 2006

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes

Por Lo, Wei-Ching, Li, Wen, Jones, Ella F., Newitt, David C., Kornak, John, Wilmes, Lisa J., Esserman, Laura J., Hylton, Nola M.
Publicado no PLoS One (2016)

Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention

Por Flowers, Chris I., O’Donoghue, Cristina, Moore, Dan, Goss, Adeline, Kim, Danny, Kim, June-Ho, Elias, Sjoerd G., Fridland, Julia, Esserman, Laura J.
Publicado em 2013

Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ

Por Meyerson, Anna F., Lessing, Juan N., Itakura, Kaoru, Hylton, Nola M., Wolverton, Dulcy E., Joe, Bonnie N., Esserman, Laura J., Hwang, E. Shelley
Publicado em 2011

Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease

Por Marks, Jeffrey R., Anderson, Karen S., Engstrom, Paul, Godwin, Andrew K., Esserman, Laura J., Longton, Gary, Iversen, Edwin S., Mathew, Anu, Patriotis, Christos, Pepe, Margaret S.
Publicado no Cancer Epidemiol Biomarkers Prev (2014)

The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context

Por Campbell, Michael J., Wolf, Denise, Mukhtar, Rita A., Tandon, Vickram, Yau, Christina, Au, Alfred, Baehner, Frederick, van’t Veer, Laura, Berry, Donald, Esserman, Laura J.
Publicado em 2013

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma <it>in situ</it>

Por Shim Veronica, Chin Koei, Swain Rebecca, Lessing Juan, Anderson Joseph, DeVries Sandy, Chen Yunn-Yi, Esserman Laura J, Waldman Frederic M, Hwang E Shelley
Publicado em 2009-08-01

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ

Por Chen, Yunn-Yi, DeVries, Sandy, Anderson, Joseph, Lessing, Juan, Swain, Rebecca, Chin, Koei, Shim, Veronica, Esserman, Laura J, Waldman, Frederic M, Hwang, E Shelley
Publicado em 2009

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Por Li, Wen, Arasu, Vignesh, Newitt, David C., Jones, Ella F., Wilmes, Lisa, Gibbs, Jessica, Kornak, John, Joe, Bonnie N., Esserman, Laura J., Hylton, Nola M.
Publicado no Tomography (2016)